What question did this study set out to answer?

To evaluate the safety and antitumor activity of AL2846 in previously treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).

April 11, 2026Clinical Cancer Research0 citations

View Full Paper

AL2846, a novel multi-kinase inhibitor, for previously treated radioiodine-refractory differentiated thyroid cancer: Exploratory clinical results from the phase Ib study

FSF. ShiHunan Cancer Hospital WCWenwen ChaiHunan Cancer Hospital HYHui Yang

Key Points

To evaluate the safety and antitumor activity of AL2846 in previously treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Phase Ib clinical trial design
Participants were previously treated with other tyrosine kinase inhibitors (TKIs)
Administration of AL2846 at a dosage of 90 mg
AL2846 demonstrated an acceptable safety profile
Promising antitumor activity observed in patients
90 mg dosage exhibited more favorable effects than lower doses

Abstract

AL2846 showed an acceptable safety profile and a promising antitumor activity in previously TKI treated RR-DTC patients, with 90 mg has a more favorable effect.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Shi et al. (Thu,) studied this question.

synapsesocial.com/papers/69d9e64e78050d08c1b76ae5 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-25-3945

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI에게 질문

Bookmark

View Full Paper